LIF–STAT3 signaling suppresses PPARα to cause lipid imbalance, while fenofibrate restores lipid homeostasis and reduces cachexia, and PPARδ activation enhances oxidative metabolism and muscle endurance (112–114). The gene discussed is PPARD; the disease is Cachexia.